NASDAQ:BCAX Bicara Therapeutics Q1 2025 Earnings Results & Report $17.26 +0.84 (+5.12%) Closing price 04:00 PM EasternExtended Trading$17.24 -0.03 (-0.14%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Bicara Therapeutics missed analyst earnings expectations in its Q1 2025 results, released May 13, 2025. The company reported EPS of -$0.68 versus the -$0.40 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2025Report DateMay 13, 2025TimeBefore Market OpensConference Call7:30 AM ET Bicara Therapeutics EPS ResultsActual EPS-$0.68Consensus EPS -$0.40Beat/MissMissed by -$0.28One Year Ago EPSN/AEPS Beat Rate2 of last 8 quartersBicara Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsBicara Therapeutics' Q3 2026 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, November 10, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Bicara Therapeutics Q1 2025 Earnings FAQ Did Bicara Therapeutics beat earnings estimates for Q1 2025? Bicara Therapeutics (NASDAQ:BCAX) reported earnings of -$0.68 per share for Q1 2025, missing the consensus estimate of -$0.40. The report was announced on Tuesday, May 13, 2025. When is Bicara Therapeutics' next earnings date? Bicara Therapeutics' next earnings date is estimated for Monday, November 9, 2026. MarketBeat tracks confirmed and estimated earnings dates for Bicara Therapeutics on the company's earnings history page. Bicara Therapeutics Earnings HeadlinesBicara Therapeutics Inc. (NASDAQ:BCAX) Stock Has Average Target Price of $32.64 According to AnalystsOctober 7 at 4:29 AM | americanbankingnews.comBicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)October 5 at 8:30 AM | globenewswire.comElon’s FINAL Warning? [US Dollar Collapse]On April 25, 2023, Elon Musk issued a stark warning about the future of the US dollar. A former Wall Street Journal personal finance expert says that prediction may now be unfolding, outlining five steps investors are weighing amid the shift.October 8 at 1:00 AM | International Living (Ad)Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)September 3, 2026 | globenewswire.comBicara Therapeutics Secures Boston Headquarters Through SubleaseAugust 25, 2026 | tipranks.comBicara Therapeutics’ Earnings Call Signals Pivotal ProgressAugust 23, 2026 | tipranks.comSee More Bicara Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Bicara Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bicara Therapeutics and other key companies, straight to your email. Email Address About Bicara TherapeuticsBicara Therapeutics (NASDAQ:BCAX) (NASDAQ: BCAX) is a clinical-stage biotechnology company focused on developing therapies for solid tumors. The company’s approach is designed to address both cancer cells and the tumor microenvironment, which can suppress immune responses and limit the effectiveness of existing treatments. Bicara’s lead product candidate is ficerafusp alfa, also known as BCA101. It is an investigational bifunctional fusion protein designed to target the epidermal growth factor receptor (EGFR) on tumor cells while blocking transforming growth factor beta (TGF-β), a signaling pathway associated with tumor growth and immune suppression. The company is evaluating ficerafusp alfa in clinical studies, including combination treatment with immune checkpoint inhibitors for patients with recurrent or metastatic head and neck squamous cell carcinoma. Based in Cambridge, Massachusetts, Bicara is developing its pipeline for cancers in which EGFR signaling and the tumor microenvironment may play important roles. Its programs remain investigational and have not been approved for commercial use by regulatory authorities.View Bicara Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Levi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueSkydance Just Became a Media Giant—With an $80 Billion Debt LoadConstellation Brands Beat Earnings, But Beer Demand Is Still a ProblemTesla's EV Delivery Beat Is In, So What Happens Now?BigBear.ai Is Heavily Shorted—and Its Fundamentals Are Starting to ChangePenguin Solutions Is Soaring as AI Memory Demand Explodes Upcoming Earnings Delta Air Lines (10/9/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
